論文・総説

​

・Azuma Y, Suzuki K., Higai K., Matsumoto K.,Tada S: Biphasic Increases of Cell Surface Calreticulin Following Treatment with Mitoxantrone. Biol Pharm Bull. 43(10):1595-1599:2020. 

 

・Kobayashi K., Higai K., Mukozu T., Matsui D., Amanuma M., Yoshimine N., Ogino Y., Matsui T., Wakui N., Shinohara M., Momiyama K., Daido Y.,, Nagai H., Igarashi Y. Tivantinib Decreases Hepatocyte Growth Factor-Induced BCRP Expression in Hepatocellular Carcinoma HepG2 Cells. Biol. Pharm. Bull. 43, 1421–1425:2020. 

 

・Ono M., Abe S., Higai K., Higashi S., Saito S.,Saito R. An improved and practical synthesis route toantiproliferative (±)-shikonin and its O-acylderivatives. Synthetic Communications 51(5), 738-746:2020. 

 

​

・Ohashi Y., Yatabe M., Niijima D., Tani K., Ogawa C., Yachi Y., Kagoo T., Boku S., Ueno H., Yano T.,

Higai K., Yokoyama A. Safety and Effectiveness of Ixazomib Dose-escalating Strategy in Ixazomib-Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma. In Vivo 34(5):2821-2828: 2020.